Does the chronic inflammatory demyelinating polyradiculoneuropathy due to secondary cause differ from primary

Neurology India

Volumn 59, Issue 5, 2011, Pages 664-668

  Wadwekar, Vaibhav ^a   Kalita, Jayantee ^a   Misra, Usha Kant ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

and skin changes; Chronic inflammatory demyelinating polyradiculoneuropathy; electrodiagnosis; endocrinopathy; idiopathic; M protein; organomegaly; outcome; polyneuropathy; secondary; treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; CLINICAL ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DISABILITY SEVERITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSAUTONOMIA; ELECTRODIAGNOSIS; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MOTOR PERFORMANCE; MYELOMA; NEUROPHYSIOLOGY; OUTCOME ASSESSMENT; POEMS SYNDROME; RADICULOPATHY; SENSORY NERVE CONDUCTION; TEACHING HOSPITAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DIABETES COMPLICATIONS; DISABILITY EVALUATION; ELECTRIC STIMULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; PARAPROTEINEMIAS; PERIPHERAL NERVES; POEMS SYNDROME; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PREDNISOLONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 81155153802     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.86537     Document Type: Article

References (25)

1. Rotta FT, Sussman AT, Bradley WG, Ram Ayyar D, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-39.
2. Verma A. Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 2001;6:8-13.
3. Rentzos M, Anyfanti C, Kaponi A, Pandis D, Ioannou M, Vassilopoulos D. Chronic inflammatory demyelinating polyneuropathy: A 6-year retrospective clinical study of a hospital-based population. J Clin Neurosci 2007;14:229-35.
4. Wicklund MP, Kissel JT. Paraproteinemic neuropathy. Curr Treat Options Neurol 2001;3:147-56.
5. Dispenzieri A. POEMS syndrome. Blood Rev 2007;21:285-99.
6. Viala K, Béhin A, Maisonobe T, Léger JM, Stojkovic T, Davi F, et al. Neuropathy in lymphoma: A relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry 2008;79:778-82.
7. Corcia P, Barbereau D, Guennoc AM, de Toffol B, Bacq Y. Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy. Neurology 2004;63:179-80.
8. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response in treatment in 67 consecutive patients with and without gammopathy. Neurology 1997;48:321-8.
9. Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002;59:751-7.
10. Kalita J, Misra UK, Yadav RK. A comparative study of chronic inflammatory demyelinating polyradiculoneuropathy with and without diabetes mellitus. Eur J Neurol 2007;14:638-43.
11. Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73:39-45.
12. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2005;10:220-8.
13. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
14. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasmaexchange therapy in chronic inflammatory demyelinating polyneuropathy: A double blind, sham controlled, cross over study. Brain 1996;119:1055-66.
15. Kalita J, Misra UK. Postural hypotension in a patient with acute myelitis. Postgrad Med J 1996;72:180-2.
16. Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, et al. The burden of diabetes and impaired fasting glucose in India using the ADA 1997 criteria: Prevalence of diabetes in India study (PODIS). Diabetes Res Clin Pract 2004;66:293-300.
17. nd ed. New Delhi: Elsevier India; 2006. p. 31-87.
18. th ed. McGraw- Hill, New York Chapter 13; 2008. p. 2080.
19. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. Diabetes Epidemiology Study Group in India: High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001;44:1094-101
20. Pickup J, William G. Epidemiology of Diebetes. Textbook of Diabetes. In: Kennedy G, editor. New York: Blackwell Science; 1991. p. 47-53.
21. Maisonobe T, Chassande B, Vérin M, Jouni M, Léger JM, Bouche P. Chronic dysimmune demyelinating polyneuropathy: A clinical and electrophysiological study of 93 patients. J Neurol Neurosurg Psychiatry 1996;61:36-42.
22. Cocito D, Durelli L, Isoardo G. Different clinical, electrophysiological and immunological features of CIDP associated with paraproteinaemia. Acta Neurol Scand 2003;108:274-80.
23. Jann S, Beretta S, Bramerio MA. Different types of chronic inflammatory demyelinating polyneuropathy have a different clinical course and response to treatment. Muscle Nerve 2005;32:351-6.
24. Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998;51:1735-8.
25. Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc 2010;8:14.